

Olavi Pelkonen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8201782/olavi-pelkonen-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182
papers

9,252
citations

52
h-index

89
g-index

209
ext. papers

9,991
ext. citations

4.2
avg, IF

5.65
L-index

#	Paper	IF	Citations
182	Characterization of furathiocarb metabolism in in-vitro human liver microsomes and recombinant cytochrome P450 enzymes.. <i>Toxicology Reports</i> , 2022 , 9, 679-689	4.8	0
181	Corrigendum to: Chloro-s-triazenes-toxicokinetic, Toxicodynamic, Human Exposure, and Regulatory Considerations.. <i>Current Drug Metabolism</i> , 2021 , 22, 996	3.5	
180	Critique of the "Comment" entitled "Pyrethroid exposure: Not so harmless after all" by Demeneix et al. (2020) published in the lancet diabetes endocrinology. <i>Toxicology Letters</i> , 2021 , 340, 1-3	4.4	
179	Development of Integrated Approaches to Testing and Assessment (IATA) case studies on developmental neurotoxicity (DNT) risk assessment. <i>EFSA Journal</i> , 2021 , 19, e06599	2.3	4
178	Chloro-s-triazines-toxicokinetic, Toxicodynamic, Human Exposure, and Regulatory Considerations. <i>Current Drug Metabolism</i> , 2021 , 22, 645-656	3.5	1
177	The EU chemicals strategy for sustainability: in support of the BfR position. <i>Archives of Toxicology</i> , 2021 , 95, 3133-3136	5.8	2
176	Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on testing and interpretation of comparative metabolism studies.. <i>EFSA Journal</i> , 2021 , 19, e06970 ^{2,3}		0
175	Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on the genotoxic potential of triazine amine (metabolite common to several sulfonylurea active substances). <i>EFSA Journal</i> , 2020 , 18, e06053	2.3	1
174	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2020 , 83, 485-494	3.2	7
173	Statement on the translocation potential by MA342 in plants after seed treatment of cereals and peas and assessment of the risk to humans. <i>EFSA Journal</i> , 2020 , 18, e06276	2.3	1
172	Inhibition and induction of CYP enzymes in humans: an update. <i>Archives of Toxicology</i> , 2020 , 94, 3671-3728	3.8	41
171	Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study. <i>Toxicology in Vitro</i> , 2019 , 60, 212-228	3.6	23
170	Scientific statement on the coverage of bats by the current pesticide risk assessment for birds and mammals. <i>EFSA Journal</i> , 2019 , 17, e05758	2.3	8
169	Scientific Opinion on the setting of health-based reference values for metabolites of the active substance terbuthylazine. <i>EFSA Journal</i> , 2019 , 17, e05712	2.3	1
168	Scientific Opinion on the state of the science on pesticide risk assessment for amphibians and reptiles. <i>EFSA Journal</i> , 2018 , 16, e05125	2.3	18
167	Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor at the Crossroads of Toxicokinetics and Toxicodynamics. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 123 Suppl 5, 42-50	3.1	24
166	Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance. <i>Toxicology in Vitro</i> , 2018 , 53, 233-244	3.6	8

165	Scientific opinion on pesticides in foods for infants and young children. <i>EFSA Journal</i> , 2018 , 16, e05286	2.3	10
164	Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms. <i>EFSA Journal</i> , 2018 , 16, e05377	2.3	38
163	Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments. <i>EFSA Journal</i> , 2018 , 16, e05382	2.3	1
162	Toxicokinetics of Herbal Products 2017 , 67-80		2
161	Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research. <i>Archives of Toxicology</i> , 2017 , 91, 2763-2780	5.8	11
160	Scientific Opinion addressing the state of the science on risk assessment of plant protection products for in-soil organisms. <i>EFSA Journal</i> , 2017 , 15, e04690	2.3	40
159	Systems Network Pharmacology-Toxicology in the Study of Herbal Medicines 2017 , 129-164		
158	Scientific Opinion of the PPR Panel on the follow-up of the findings of the External Scientific Report Literature review of epidemiological studies linking exposure to pesticides and health effects <i>EFSA Journal</i> , 2017 , 15, e05007	2.3	11
157	Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson disease and childhood leukaemia. <i>EFSA Journal</i> , 2017 , 15, e04691	2.3	12
156	Cardiac safety of ophthalmic timolol. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1549-1561	4.1	35
155	Upholding science in health, safety and environmental risk assessments and regulations. <i>Toxicology</i> , 2016 , 371, 12-16	4.4	5
154	Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species. <i>Drug Metabolism and Personalized Therapy</i> , 2016 , 31, 35-40	2	2
153	Tandem mass spectrometric analysis of S- and N-linked glutathione conjugates of pulegone and menthofuran and identification of P450 enzymes mediating their formation. <i>Rapid Communications in Mass Spectrometry</i> , 2016 , 30, 917-26	2.2	13
152	Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 115, 345-51	3.5	9
151	Analytical challenges for conducting rapid metabolism characterization for QIVIVE. <i>Toxicology</i> , 2015 , 332, 20-9	4.4	16
150	Drug Metabolism - From In Vitro to In Vivo, From Simple to Complex: Reflections of the BCPT Nordic Prize 2014 Awardee. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015 , 117, 147-55	3.1	3
149	Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System. <i>Toxicological Sciences</i> , 2015 , 146, 11-5	4.4	19
148	Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data. <i>Toxicology</i> , 2015 , 332, 8-19	4.4	56

147	Reactive metabolites in early drug development: predictive in vitro tools. <i>Current Medicinal Chemistry</i> , 2015 , 22, 538-50	4.3	13
146	Differentiation-Promoting Medium Additives for Hepatocyte Cultivation and Cryopreservation. <i>Methods in Molecular Biology</i> , 2015 , 1250, 143-59	1.4	4
145	Biomarkers of toxicity in human placenta 2014 , 325-360		1
144	Human variation and CYP enzyme contribution in benfuracarb metabolism in human in vitro hepatic models. <i>Toxicology Letters</i> , 2014 , 224, 300-9	4.4	16
143	Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?. <i>Journal of Traditional and Complementary Medicine</i> , 2014 , 4, 1-7	4.6	48
142	Comparative metabolism of benfuracarb in in vitro mammalian hepatic microsomes model and its implications for chemical risk assessment. <i>Toxicology Letters</i> , 2014 , 224, 290-9	4.4	16
141	Consideration of Metabolism in In Vitro Cellular Systems. <i>Methods in Pharmacology and Toxicology</i> , 2014 , 501-519	1.1	
140	Estimation of health risk by using toxicokinetic modelling: a case study of polychlorinated biphenyl PCB153. <i>Journal of Hazardous Materials</i> , 2013 , 261, 1-10	12.8	14
139	Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. <i>Biopharmaceutics and Drug Disposition</i> , 2013 , 34, 387-95	1.7	7
138	Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. <i>Toxicology in Vitro</i> , 2013 , 27, 1570-7	3.6	92
137	Preservation, induction or incorporation of metabolism into the in vitro cellular system - views to current opportunities and limitations. <i>Toxicology in Vitro</i> , 2013 , 27, 1578-83	3.6	9
136	The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches. <i>Toxicology in Vitro</i> , 2013 , 27, 1584-8	3.6	31
135	Thujone and thujone-containing herbal medicinal and botanical products: toxicological assessment. <i>Regulatory Toxicology and Pharmacology</i> , 2013 , 65, 100-7	3.4	82
134	Open letter to the European Commission: scientifically unfounded precaution drives European Commission recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles. <i>Archives of Toxicology</i> , 2013 , 87, 1739-41	5.8	11
133	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. <i>Drug Metabolism and Drug Interactions</i> , 2013 , 28, 153-61		10
132	Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 14064-75	6.3	8
131	Characterization of human cytochrome P450 induction by pesticides. <i>Toxicology</i> , 2012 , 294, 17-26	4.4	59
130	Significant interspecies differences in induction profiles of hepatic CYP enzymes by TCDD in bank and field voles. <i>Environmental Toxicology and Chemistry</i> , 2012 , 31, 663-71	3.8	7

129	Omics and its potential impact on R&D and regulation of complex herbal products. <i>Journal of Ethnopharmacology</i> , 2012 , 140, 587-93	5	50
128	Review of current and "omics" methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms. <i>Journal of Ethnopharmacology</i> , 2012 , 140, 492-512	5	99
127	Hepatocytes: the powerhouse of biotransformation. <i>International Journal of Biochemistry and Cell Biology</i> , 2012 , 44, 257-61	5.6	41
126	A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2012 , 29, 3-91	4.3	153
125	In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 483-91	6.2	26
124	Metabolism of ophthalmic timolol: new aspects of an old drug. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011 , 108, 297-303	3.1	37
123	Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. <i>Archives of Toxicology</i> , 2011 , 85, 367-485	5.8	398
122	Metabolism of Ethujone in human hepatic preparations in vitro. <i>Xenobiotica</i> , 2011 , 41, 101-11	2	27
121	Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 106, 302-9	3.1	13
120	Predictive toxicity: grand challenges. <i>Frontiers in Pharmacology</i> , 2010 , 1, 3	5.6	6
119	Xenobiotic metabolism of bank vole (<i>Myodes glareolus</i>) exposed to PCDDs. <i>Environmental Toxicology and Pharmacology</i> , 2010 , 29, 19-23	5.8	3
118	Placental transfer and DNA binding of benzo(a)pyrene in human placental perfusion. <i>Toxicology Letters</i> , 2010 , 197, 75-81	4.4	47
117	Overview of the metabolism and interactions of pesticides in hepatic in vitro systems. <i>International Journal of Environmental Analytical Chemistry</i> , 2010 , 90, 429-437	1.8	4
116	Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. <i>Chemico-Biological Interactions</i> , 2010 , 185, 163-73	5	21
115	Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD		17
114	An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes. <i>Journal of Environmental Science and Health - Part B Pesticides, Food Contaminants, and Agricultural Wastes</i> , 2009 , 44, 553-63	2.2	49
113	Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. <i>Drug Discovery Today</i> , 2009 , 14, 120-33	8.8	109
112	Metabolism of carbosulfan. I. Species differences in the in vitro biotransformation by mammalian hepatic microsomes including human. <i>Chemico-Biological Interactions</i> , 2009 , 181, 210-9	5	24

111	Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2009 , 23, 843-55	2.2	71
110	Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 867-87	6.4	6
109	Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. <i>Toxicology in Vitro</i> , 2009 , 23, 748-53	3.6	81
108	From known knowns to known unknowns: predicting in vivo drug metabolites. <i>Bioanalysis</i> , 2009 , 1, 393-414	4.1	22
107	Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes - a preliminary analysis. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2009 , 26, 214-22	4.3	20
106	Coactivator PGC-1alpha regulates the fasting inducible xenobiotic-metabolizing enzyme CYP2A5 in mouse primary hepatocytes. <i>Toxicology and Applied Pharmacology</i> , 2008 , 232, 135-41	4.6	31
105	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008 , 110, 56-66	5.1	30
104	Local kinetics and dynamics of xenobiotics. <i>Critical Reviews in Toxicology</i> , 2008 , 38, 697-720	5.7	34
103	Inhibition and induction of human cytochrome P450 enzymes: current status. <i>Archives of Toxicology</i> , 2008 , 82, 667-715	5.8	410
102	Selegiline Metabolism and Cytochrome P450 Enzymes: In vitro Study in Human Liver Microsomes*. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008 , 86, 215-221		
101	Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column. <i>Journal of Chromatography A</i> , 2008 , 1215, 107-15	4.5	47
100	In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. <i>Journal of Mass Spectrometry</i> , 2007 , 42, 960-6	2.2	78
99	Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. <i>Current Drug Metabolism</i> , 2007 , 8, 33-45	3.5	349
98	Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 1135-41	4	41
97	The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. <i>Current Drug Metabolism</i> , 2006 , 7, 705-14	3.5	99
96	Cytochrome P450 (CYP) inhibition screening: comparison of three tests. <i>European Journal of Pharmaceutical Sciences</i> , 2006 , 29, 130-8	5.1	45
95	Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts. <i>Bone</i> , 2006 , 39, 1026-1034	4.7	56
94	Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. <i>ATLA Alternatives To Laboratory Animals</i> , 2006 , 34, 49-84	2.1	124

93	In vitro screening of drug metabolism during drug development: can we trust the predictions?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005 , 1, 49-59	5.5	34
92	Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 553-9	6.1	116
91	Prediction of drug metabolism and interactions on the basis of in vitro investigations. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005 , 96, 167-75	3.1	108
90	Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. <i>European Journal of Pharmaceutical Sciences</i> , 2005 , 24, 123-32	5.1	113
89	A simple method for differentiation of monoisotopic drug metabolites with hydrogen-deuterium exchange liquid chromatography/electrospray mass spectrometry. <i>European Journal of Pharmaceutical Sciences</i> , 2005 , 25, 155-62	5.1	33
88	Toxicokinetics and metabolism. <i>ATLA Alternatives To Laboratory Animals</i> , 2005 , 33 Suppl 1, 147-75	2.1	13
87	Regulation of the Cyp2a5 gene involves an aryl hydrocarbon receptor-dependent pathway. <i>Molecular Pharmacology</i> , 2005 , 67, 1325-33	4.3	52
86	In vitro methods in the prediction of kinetics of drugs: focus on drug metabolism. <i>ATLA Alternatives To Laboratory Animals</i> , 2004 , 32, 425-30	2.1	11
85	Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 626-31	4	87
84	Regulation of Cyp2a5 transcription in mouse primary hepatocytes: roles of hepatocyte nuclear factor 4 and nuclear factor I. <i>Biochemical Journal</i> , 2004 , 381, 887-94	3.8	20
83	Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 304, 745-52	4.7	82
82	Dual action of oestrogens on the mouse constitutive androstane receptor. <i>Biochemical Journal</i> , 2003 , 376, 465-72	3.8	34
81	Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 326-33	6.1	59
80	Cytochrome P450 enzyme activity in five herbivorous, non-passerine bird species. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2003 , 134, 69-77	3.2	8
79	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 1093-102	4	72
78	Lack of association between CYP2A5 induction and apoptosis in mouse primary hepatocytes. <i>Biochemical Pharmacology</i> , 2002 , 63, 429-35	6	2
77	Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002 , 90, 155-60		33
76	Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. <i>Critical Reviews in Toxicology</i> , 2002 , 32, 391-411	5.7	238

75	Human CYPs: in vivo and clinical aspects. <i>Drug Metabolism Reviews</i> , 2002 , 34, 37-46	7	33
74	Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. <i>Neonatology</i> , 2001 , 80, 193-201	4	58
73	Polymorphisms of CYP2A6 and its practical consequences. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 357-63	3.8	115
72	The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. <i>Breast Cancer Research and Treatment</i> , 2001 , 70, 47-54	4.4	78
71	In vitro prediction of gastrointestinal absorption and bioavailability: an experts meeting report. <i>European Journal of Clinical Pharmacology</i> , 2001 , 57, 621-9	2.8	49
70	CYP2A6: a human coumarin 7-hydroxylase. <i>Toxicology</i> , 2000 , 144, 139-47	4.4	188
69	Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000 , 22, 360-6	5.7	134
68	Expression of CYP2A genes in human liver and extrahepatic tissues. <i>Biochemical Pharmacology</i> , 1999 , 57, 1407-13	6	131
67	Modulation of murine phenobarbital-inducible CYP2A5, CYP2B10 and CYP1A enzymes by inhibitors of protein kinases and phosphatases. <i>FEBS Journal</i> , 1999 , 264, 19-26		19
66	Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. <i>FEBS Letters</i> , 1999 , 448, 105-10	3.8	147
65	Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. <i>FEBS Letters</i> , 1999 , 460, 321-7	3.8	135
64	CYP2D6 polymorphism is not crucial for the disposition of selegiline. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 402-11	6.1	20
63	Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1998 , 82, 93-7		41
62	Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1998 , 82, 161-6		32
61	Developmental expression of cytochrome P450 enzymes in human liver. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1998 , 82, 209-17		88
60	Cytochrome P450 2A6 (CYP2A6) expression in human hepatocellular carcinoma. <i>Hepatology</i> , 1998 , 27, 427-32	11.2	43
59	Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes. <i>Archives of Toxicology</i> , 1998 , 72, 336-41	5.8	13
58	Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. <i>FEBS Letters</i> , 1998 , 438, 201-5	3.8	106

57	Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. <i>Critical Reviews in Toxicology</i> , 1998 , 28, 35-72	5.7	178
56	CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 247-50		29
55	Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. <i>Toxicology</i> , 1997 , 123, 177-84	4.4	50
54	Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450s in human bronchoalveolar macrophages and peripheral blood lymphocytes. <i>Molecular Carcinogenesis</i> , 1997 , 20, 224-30	5	76
53	Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 331-9	6.1	339
52	Regulation of CYP 2 A 5 induction by porphyrinogenic agents in mouse primary hepatocytes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997 , 355, 8-13	3.4	13
51	Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review. <i>Gene</i> , 1995 , 159, 113-21	3.8	217
50	Individual expression of carcinogen-metabolizing enzymes: cytochrome P4502A. <i>Journal of Occupational and Environmental Medicine</i> , 1995 , 37, 19-24	2	17
49	Transfer of lidocaine and bupivacaine across the isolated perfused human placenta. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1995 , 77, 142-8		39
48	Thyroid and myocardial function after replacement of carbamazepine by oxcarbazepine. <i>Epilepsia</i> , 1995 , 36, 810-6	6.4	40
47	The expression and environmental regulation of P450 enzymes in human placenta. <i>Critical Reviews in Toxicology</i> , 1994 , 24, 211-29	5.7	92
46	Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. <i>Epilepsia</i> , 1994 , 35, 1217-20	6.4	73
45	Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. <i>Biochemical Pharmacology</i> , 1994 , 48, 59-64	6	167
44	Metabolic interactions of methoxsalen and coumarin in humans and mice. <i>Biochemical Pharmacology</i> , 1994 , 48, 1363-9	6	44
43	Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and in healthy men. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 9-13	6.1	23
42	Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells. <i>European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section</i> , 1993 , 248, 95-102		11
41	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1993 , 44, 61-7	5.1	49
40	Cytochrome P4502A-mediated coumarin 7-hydroxylation and testosterone hydroxylation in mouse and rat lung. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993 , 72, 107-12		26

39	Involvement of P450 1A1 in benzo(a)pyrene but not in benzo(a)pyrene-7,8-dihydrodiol activation by 3-methylcholanthrene-induced mouse liver microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993 , 73, 319-24		6
38	Cytochrome P450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse. <i>Biochemical Pharmacology</i> , 1993 , 45, 899-907	6	38
37	Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. <i>Pharmacogenetics and Genomics</i> , 1992 , 2, 227-33		143
36	Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1991 , 69, 189-94		16
35	Comparison between cobalt and pyrazole in the increased expression of coumarin 7-hydroxylase in mouse liver. <i>Biochemical Pharmacology</i> , 1991 , 41, 462-5	6	17
34	Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450-dependent monooxygenase activities. <i>Toxicology</i> , 1990 , 62, 175-87	4.4	48
33	Inhibition of hepatic microsomal drug metabolism in rats by five calcium antagonists. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1989 , 64, 446-50		13
32	Preferential inhibition of mouse hepatic coumarin 7-hydroxylase by inhibitors of steroid metabolizing monooxygenases. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1989 , 65, 104-9		5
31	Comparison of the formation of benzo[a]pyrene diolepoxide-DNA adducts in vitro by rat and human microsomes: evidence for the involvement of P-450IA1 and P-450IA2. <i>Journal of Biochemical Toxicology</i> , 1989 , 4, 79-86		52
30	Human placental xenobiotic and steroid biotransformations catalyzed by cytochrome P450, epoxide hydrolase, and glutathione S-transferase activities and their relationships to maternal cigarette smoking. <i>Drug Metabolism Reviews</i> , 1989 , 21, 427-61	7	28
29	Pyrazole is different from acetone and ethanol as an inducer of the polysubstrate monooxygenase system in mice: evidence that pyrazole-inducible P450Coh is distinct from acetone-inducible P450ac. <i>Archives of Biochemistry and Biophysics</i> , 1988 , 267, 589-98	4.1	23
28	Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. <i>Biochemical Pharmacology</i> , 1988 , 37, 3889-95	6	118
27	Environmental factors of enzyme induction and inhibition 1987 , 33, 115-20		10
26	Aryl hydrocarbon hydroxylase in lymphocytes and lung tissue from lung cancer patients and controls. <i>International Journal of Cancer</i> , 1987 , 39, 565-70	7.5	45
25	Cholesterol side-chain cleavage activity in human placenta and bovine adrenals: an one-step method for separation of pregnenolone formed in vitro. <i>Steroids</i> , 1984 , 43, 517-27	2.8	11
24	Enzymology and regulation of xenobiotic and steroid metabolism in placenta. <i>Biochemical Society Transactions</i> , 1984 , 12, 42-4	5.1	18
23	Effects of cigarette smoke on rat lung and liver ornithine decarboxylase and aryl hydrocarbon hydroxylase activities and lung benzo(a)pyrene metabolism. <i>Acta Pharmacologica Et Toxicologica</i> , 1983 , 52, 168-74		17
22	Cigarette smoking and drug metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 375-80	6.1	29

21	Drug metabolism in alcoholics 1982 , 16, 261-8		25
20	Binding of polycyclic aromatic hydrocarbons to DNA: comparison with mutagenesis and tumorigenesis. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1980 , 6, 1009-20	3.2	20
19	The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. <i>Biochemical Pharmacology</i> , 1980 , 29, 3075-80	6	133
18	Effects of various in vitro--inhibitors of benzo(a)pyrene metabolism in isolated rat lung perfusion. <i>Acta Pharmacologica Et Toxicologica</i> , 1979 , 45, 1-8		7
17	Effects of microsomal enzyme inducers in vivo and inhibitors in vitro on the covalent binding of benzo[a]pyrene metabolites to DNA catalyzed by liver microsomes from genetically responsive and nonresponsive mice. <i>Biochemical Pharmacology</i> , 1979 , 28, 111-21	6	27
16	Cimetidine inhibits microsomal drug metabolism in the rat. <i>European Journal of Pharmacology</i> , 1979 , 55, 335-6	5.3	103
15	The metabolism of benzo(a)pyrene in isolated perfused lungs from variously-treated rats. <i>Acta Pharmacologica Et Toxicologica</i> , 1977 , 41, 129-40		35
14	Differential inhibition of aryl hydrocarbon hydroxylase in human foetal liver, adrenal gland and placenta*. <i>Acta Pharmacologica Et Toxicologica</i> , 1977 , 41, 306-16		29
13	Cytochrome P-450 and drug-induced spectral interactions in the hepatic microsomes of trout, <i>Salmo trutta lacustris</i> . <i>Acta Pharmacologica Et Toxicologica</i> , 1976 , 38, 440-9		35
12	Properties of benzpyrene hydroxylase from human liver and comparison with the rat, rabbit and guinea-pig enzymes. <i>Xenobiotica</i> , 1975 , 5, 501-9	2	27
11	Metabolism of polycyclic hydrocarbons by a highly active aryl hydrocarbon hydroxylase system in the liver of a trout species. <i>Biochemical and Biophysical Research Communications</i> , 1975 , 63, 635-41	3.4	62
10	Spectral interactions of a series of chlorinated hydrocarbons with cytochrome P-450 of liver microsomes from variously-treated rats. <i>FEBS Letters</i> , 1975 , 51, 11-4	3.8	25
9	Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. <i>Chemico-Biological Interactions</i> , 1974 , 9, 205-16	5	65
8	Drug metabolism in human fetal tissues. <i>Life Sciences</i> , 1973 , 13, 1163-1180	6.8	42
7	3,4-Benzpyrene and aniline are hydroxylated by human fetal liver but not by placenta at 6-7 weeks of fetal age. <i>Biochemical Pharmacology</i> , 1973 , 22, 1538-40	6	14
6	Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. <i>Clinical Pharmacology and Therapeutics</i> , 1973 , 14, 840-6	6.1	101
5	Metabolism of chlorpromazine and p-nitrobenzoic acid in the liver, intestine and kidney of the human foetus. <i>Acta Pharmacologica Et Toxicologica</i> , 1971 , 29, 284-94		39
4	Demonstration of cytochrome P-450 in human foetal liver microsomes in early pregnancy. <i>Acta Pharmacologica Et Toxicologica</i> , 1971 , 30, 158-60		23

- 3 3,4-Benzpyrene and N-methylaniline metabolizing enzymes in the immature human foetus and placenta. *Acta Pharmacologica Et Toxicologica*, **1971**, 30, 385-95 56
- 2 In Vitro Metabolism in Preclinical Drug Development1
- 1 In Vitro Metabolism in Preclinical Drug Development743-774 4